- Home
- PSNL vs VALN Comparison
PSNL vs VALN Comparison
Compare PSNL & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- VALN
- Stock Information
- Founded
- PSNL 2011
- VALN 2012
- Country
- PSNL United States
- VALN France
- Employees
- PSNL N/A
- VALN N/A
- Industry
- PSNL Medical Specialities
- VALN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PSNL Health Care
- VALN Health Care
- Exchange
- PSNL Nasdaq
- VALN Nasdaq
- Market Cap
- PSNL 576.8M
- VALN 542.5M
- IPO Year
- PSNL 2019
- VALN 2021
- Fundamental
- Price
- PSNL $6.03
- VALN $5.50
- Analyst Decision
- PSNL Strong Buy
- VALN Strong Buy
- Analyst Count
- PSNL 5
- VALN 3
- Target Price
- PSNL $8.00
- VALN $15.33
- AVG Volume (30 Days)
- PSNL 993.9K
- VALN 9.1K
- Earning Date
- PSNL 08-06-2025
- VALN 08-12-2025
- Dividend Yield
- PSNL N/A
- VALN N/A
- EPS Growth
- PSNL N/A
- VALN N/A
- EPS
- PSNL N/A
- VALN N/A
- Revenue
- PSNL $85,694,000.00
- VALN $201,099,222.00
- Revenue This Year
- PSNL $0.45
- VALN $18.74
- Revenue Next Year
- PSNL $25.75
- VALN $29.26
- P/E Ratio
- PSNL N/A
- VALN N/A
- Revenue Growth
- PSNL 15.57
- VALN 21.64
- 52 Week Low
- PSNL $1.14
- VALN $3.62
- 52 Week High
- PSNL $7.20
- VALN $8.66
- Technical
- Relative Strength Index (RSI)
- PSNL 61.71
- VALN 29.05
- Support Level
- PSNL $6.01
- VALN $5.43
- Resistance Level
- PSNL $6.72
- VALN $6.40
- Average True Range (ATR)
- PSNL 0.43
- VALN 0.22
- MACD
- PSNL 0.01
- VALN -0.06
- Stochastic Oscillator
- PSNL 61.02
- VALN 7.18
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About VALN Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.